In addition, other investigational therapeutics that target FGFR fusions/rearrangements are currently being tested in first- and second-line settings for metastatic iCCA, underlining the significance of FGFR inhibitors for the treatment of patients with iCCA containing FGFR2 fusions/rearrangements [33]. The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.